{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:00:38Z","timestamp":1790190038807,"version":"4.1.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Gilead Sciences, Inc","id":[{"id":"https:\/\/ror.org\/056546b03","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Contemporary real-world evidence in advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma (GC\/GEJC\/EAC) remains limited. This study evaluated real-world treatment patterns and clinical outcomes in patients with advanced GC\/GEJC\/EAC treated with first-line therapy in the United States.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>Treatment patterns were assessed in adults from the Flatiron database with advanced or metastatic HER2-negative GC\/GEJC\/EAC who initiated first-line treatment between May 1, 2021, and July 31, 2025 (overall cohort). Clinical outcomes were assessed using the Kaplan\u2013Meier method in a subcohort with \u22656\u2009months of follow\u2011up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 2340 eligible patients, the most common first-line regimen was IO+FOLFOX\/CAPOX (31.6%). This regimen was used in 47.6% of patients with programmed cell death ligand 1 (PD-L1) combined positive score (CPS)\u2009\u2265\u20091 expression. Starting in 2024, zolbetuximab+FOLFOX\/CAPOX was administered more frequently in patients with CPS &amp;lt;1 vs \u22651 (6.1% vs 1.9%) and CPS &amp;lt;5 vs \u22655 (4.6% vs 0.8%) expression. In the subcohort (n\u2009=\u20092117), IO+FOLFOX\/CAPOX vs FOLFOX\/CAPOX was associated with significantly longer median (months; hazard ratio [95% CI]) real-world overall survival (12.3 vs 11.3; 0.81 [0.69-0.94]), time to next treatment or death (8.0 vs 6.1; 0.64 [0.55-0.75]), and time to treatment discontinuation (6.0 vs 3.0; 0.54 [0.47-0.63]). Differences in outcomes were driven by patients with CPS \u22651 expression, with no differences in patients with CPS &amp;lt;1 expression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>IO+FOLFOX\/CAPOX was the most frequent first-line regimen in advanced or metastatic GC\/GEJC\/EAC and showed improved real-world outcomes vs FOLFOX\/CAPOX. Despite these gains, overall survival remains poor, underscoring unmet needs and the importance of biomarker-informed treatment selection.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag350","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T11:52:42Z","timestamp":1788954762000},"source":"Crossref","is-referenced-by-count":0,"title":["Real-world treatment landscape and clinical outcomes in first-line advanced or metastatic gastroesophageal adenocarcinoma in the United States"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-5517-6313","authenticated-orcid":false,"given":"Jin","family":"Gu","sequence":"first","affiliation":[{"name":"Gilead Sciences , Foster City, CA 94404,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivani K","family":"Mhatre","sequence":"additional","affiliation":[{"name":"Gilead Sciences , Foster City, CA 94404,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel O","family":"Koralek","sequence":"additional","affiliation":[{"name":"Gilead Sciences , Foster City, CA 94404,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravindra","family":"Gupta","sequence":"additional","affiliation":[{"name":"Gilead Sciences , Foster City, CA 94404,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaffer A","family":"Ajani","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center , Houston, TX 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"2026092314103998100_oyag350-B1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2026092314103998100_oyag350-B2","author":"Surveillance, Epidemiology, and End Results (SEER) Program Cancer Stat Facts","year":"2026"},{"key":"2026092314103998100_oyag350-B3","author":"Surveillance, Epidemiology, and End Results (SEER) Program Cancer Stat Facts","year":"2026"},{"key":"2026092314103998100_oyag350-B4","author":"Tislelizumab. Package insert","year":"2025"},{"key":"2026092314103998100_oyag350-B5","author":"Pembrolizumab","year":"2025"},{"key":"2026092314103998100_oyag350-B6","author":"Nivolumab. Package insert","year":"2025"},{"key":"2026092314103998100_oyag350-B7","author":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for esophageal and esophagogastric junction cancers"},{"key":"2026092314103998100_oyag350-B8","author":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for gastric cancer"},{"key":"2026092314103998100_oyag350-B9","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1200\/JCO.2026.44.2_suppl.306","article-title":"REPERTOIRE: Real-world treatment (tx) patterns and outcomes in US patients (pts) with HER2-negative (HER2-) advanced gastric, gastroesophageal junction and esophageal adenocarcinoma (GC\/GEJC\/EAC)","volume":"44","author":"Shah","year":"2026","journal-title":"J Clin Oncol"},{"key":"2026092314103998100_oyag350-B10","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1200\/JCO.2024.42.3_suppl.295","article-title":"Real-world (RW) effectiveness of nivolumab plus chemotherapy (NIVO\u2009+\u2009chemo) in patients (pts) with advanced or metastatic gastric carcinoma, gastroesophageal junction carcinoma, or esophageal adenocarcinoma (GC\/GEJC\/EAC)","volume":"42","author":"Chau","year":"2024","journal-title":"JCO"},{"key":"2026092314103998100_oyag350-B11","doi-asserted-by":"publisher","first-page":"1463017","DOI":"10.3389\/fimmu.2024.1463017","article-title":"Immunotherapy plus chemotherapy versus chemotherapy alone in the first-line treatment for advanced gastric cancer\/gastroesophageal junction cancer: a real-world retrospective study","volume":"15","author":"Xu","year":"2024","journal-title":"Front Immunol"},{"key":"2026092314103998100_oyag350-B12","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.clcc.2019.09.001","article-title":"Real-world treatment patterns and clinical outcomes across lines of therapy in patients with advanced\/metastatic gastric or gastroesophageal junction cancer","volume":"19","author":"Le","year":"2020","journal-title":"Clin Colorectal Cancer"},{"key":"2026092314103998100_oyag350-B13","doi-asserted-by":"publisher","first-page":"100144","DOI":"10.1016\/j.esmorw.2025.100144","article-title":"Local and Central testing for HER2, PD-L1, MSI\/MMR, EBV, and CLDN18.2 in advanced gastric cancer: results from the SAPHIR registry","volume":"8","author":"Potthoff","year":"2025","journal-title":"ESMO Real World Data Digit Oncol"},{"key":"2026092314103998100_oyag350-B14","doi-asserted-by":"publisher","first-page":"4460","DOI":"10.1111\/1475-6773.12872","article-title":"Development and validation of a high-quality composite real-world mortality endpoint","volume":"53","author":"Curtis","year":"2018","journal-title":"Health Serv Res"},{"key":"2026092314103998100_oyag350-B15","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s12325-020-01567-9","article-title":"A comparison of real-world treatment patterns and clinical outcomes in patients receiving first-line therapy for unresectable advanced gastric or gastroesophageal junction cancer versus esophageal adenocarcinomas","volume":"38","author":"Shankaran","year":"2021","journal-title":"Adv Ther"},{"key":"2026092314103998100_oyag350-B16","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1200\/JCO.2024.42.3_suppl.275","article-title":"Real-world treatment patterns, testing patterns, and clinical outcomes of first-line (1L) therapy for metastatic gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma (mGC\/GEJC\/EAC)","volume":"42","author":"Kakehi","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026092314103998100_oyag350-B17","doi-asserted-by":"publisher","first-page":"S140","DOI":"10.1016\/j.jval.2025.04.2022","article-title":"Treatment patterns, clinical outcomes, healthcare resource utilization, and healthcare costs among patients with metastatic gastric\/gastroesophageal junction cancer in Medicare beneficiaries","volume":"28","author":"Chen","year":"2025","journal-title":"Value Health"},{"key":"2026092314103998100_oyag350-B18","article-title":"FDA ODAC finds limited benefit for checkpoint inhibitors in low PD-L1 gastric cancer","author":"Serani","journal-title":"Targeted Oncology"},{"key":"2026092314103998100_oyag350-B19","article-title":"PD-L1 expression and immune checkpoint inhibitors for the treatment of HER2 negative advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma","author":"Lemery","journal-title":"Oncologic Drugs Advisory Committee (ODAC) Meeting"},{"key":"2026092314103998100_oyag350-B20","author":"FDA Center for Drug Evaluation and Research"},{"key":"2026092314103998100_oyag350-B21","author":"Zolbetuximab","year":"2025"},{"key":"2026092314103998100_oyag350-B22","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","article-title":"Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial","volume":"401","author":"Shitara","year":"2023","journal-title":"Lancet"},{"key":"2026092314103998100_oyag350-B23","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","article-title":"Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial","volume":"29","author":"Shah","year":"2023","journal-title":"Nat Med"},{"key":"2026092314103998100_oyag350-B24","first-page":"2024","volume-title":"Poster presented at: ESMO Gastrointestinal Cancers Congress","author":"Klempner","year":"2024"},{"key":"2026092314103998100_oyag350-B25","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol"},{"key":"2026092314103998100_oyag350-B26","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1200\/JCO.23.01601","article-title":"First-line nivolumab plus chemotherapy for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 3-year follow-up of the phase III CheckMate 649 trial","volume":"42","author":"Janjigian","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026092314103998100_oyag350-B27","doi-asserted-by":"publisher","first-page":"e078876","DOI":"10.1136\/bmj-2023-078876","article-title":"Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial","volume":"385","author":"Qiu","year":"2024","journal-title":"BMJ"},{"key":"2026092314103998100_oyag350-B28","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"2026092314103998100_oyag350-B29","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1093\/annonc\/mdz060","article-title":"Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung cancer","volume":"30","author":"Blumenthal","year":"2019","journal-title":"Ann Oncol"},{"key":"2026092314103998100_oyag350-B30","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.3390\/cancers12082311","article-title":"Time to next treatment as a meaningful endpoint for trials of primary cutaneous lymphoma","volume":"12","author":"Campbell","year":"2020","journal-title":"Cancers (Basel)"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag350\/71008265\/oyag350.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/10\/oyag350\/71008265\/oyag350.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/10\/oyag350\/71008265\/oyag350.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:10:48Z","timestamp":1790187048000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag350\/8789326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,9,9]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag350","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,9,9]]},"article-number":"oyag350"}}